Soluble interleukin-2 receptor in primary and secondary Sjogren's syndrome

British Journal of Rheumatology

Volumn 36, Issue 2, 1997, Pages 194-197

  Tomas S ^a   Coll, J ^b,d   Palazon X ^c  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Laboratori Referencia de Catalunya   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

Sjogren's syndrome; Soluble interleukin 2 receptor

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; INTERLEUKIN 2 RECEPTOR;

ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SALIVARY GLAND DISEASE; SJOEGREN SYNDROME;

EID: 0030843111     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.2.194     Document Type: Article

References (16)

1. O'Garra A. Interleukins and the immune system. Lancet 1989;1:943-7.
2. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in citro. J Immunol 1985;135:3172-7.
3. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990;113:619-27.
4. Campen DH, Horwitz DA, Quismorio FP, Ehresmann GK, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358-64.
5. Miller FW, Love LA, Turitty SA, Plotz PH. Soluble CD8 and interleukin-2 receptors are measures of disease activity in the idiopathic inflammatory myopathy. Arthritis Rheum 1989;33:S33.
6. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin-2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989;50:321-32.
7. Harrington L, Affleck G, Urrows S, Tennen H, Higgins P, Zaustra A et al. Temporal covariation of soluble interleukin-2 receptor levels, daily stress, and disease activity in rheumatoid arthritis. Arthritis Rheum 1993;36:199-203.
8. Waldmann TA. Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity and immunodeficiency. Clin Immunol Immunopathol 1991;61:37-46.
9. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein R et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
10. Coll J, Tomás S, Vilella R, Corominas J. Interleukin-2 receptor expression in salivary glands of patients with Sjögren's syndrome. J Rheumatol 1995;22:1488-91.
11. Peter JB, Agopian MS, Clements PJ, Telian NS, Furst DE. Elevated serum levels of interleukin-2 receptor and IL2 in diffuse and limited scleroderma. Arthritis Rheum 1989;32:S77.
12. Degiannis D, Siebold JR, Czarnecki M, Raskova J, Rasha K. Soluble IL2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 1990;33:375-80.
13. Diamant M, Tvede N, Prause JU, Oxholm P. Soluble interleukin-2 receptors in serum from patients with primary Sjögren's syndrome. Scand J Rheumatol 1991;20:370-2.
14. Moutsopoulos HM. New insights into the physiopathology of primary Sjögren's syndrome. Ann Med Interne (Paris) 1990;141:53-6.
15. Adamson TA, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8.
16. Fox RI, Theofilopoulos AN, Altman A. Production of interleukin 2 (IL2) by salivary gland lymphocytes in Sjögren's syndrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL 2. J Immunol 1985;135:3109-15.